- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03251391
Cardiac Rehabilitation Program in Peripheral Arterial Disease
To Assess the Safety and Feasibility of a Structured Cardiac Rehabilitation Program in Patients With Peripheral Arterial Disease After Successful Revascularization Procedures: A Pilot Study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with PAD post-revascularization (stent, angioplasty, or bypass).
- Patients must have the ability to ambulate safely without assistance and should not have plans for undergoing further staged revascularization procedures.
Exclusion Criteria:
- Below or above the knee amputation.
- Underlying cardiopulmonary or other co-morbidity that would be an exclusion under currently approved standard CR protocols at the University of Kansas Medical Center (KUMC).
- Unfavorable short term prognosis and limited life expectancy (<2 years)
- Awaiting a planned staged revascularization in same or other leg (patients will be eligible once no further procedures are planned).
- Prior history of having dropped out of CR without completing.
- Unwilling to consent for all aspects of CR or study participation.
- Unable to come for CR (this will exclude patients who live far away or have no means to travel to the CR facility).
- Pregnancy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cardiac Rehabilitation Group
Participants randomized to this group will undergo cardiac rehabilitation program.
|
Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months. Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information. |
|
Aktiv komparator: Control Group
Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
|
Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in 6 minute walk test
Tidsramme: Change from Baseline to Up to 6 Months
|
Results will be measured in meters.
|
Change from Baseline to Up to 6 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Short Form Health Survey 36 (SF-36)
Tidsramme: Change from Baseline to Up to 6 Months
|
Change in quality of life measured using the SF-36.
The survey has 36 questions and measure eight health dimensions.
The scores range from 0-100.
A higher score represents less disability.
A lower score represents more disability.
|
Change from Baseline to Up to 6 Months
|
|
Short Form Health Survey 36 (SF-36)
Tidsramme: Change from Baseline to Week 18
|
Change in quality of life measured using the SF-36.
The survey has 36 questions and measure eight health dimensions.
The scores range from 0-100.
A higher score represents less disability.
A lower score represents more disability.
|
Change from Baseline to Week 18
|
|
Vascular Quality of Life Questionnaire-6 (VascuQol6)
Tidsramme: Change from Baseline to Up to 6 Months
|
The six-item Vascular Quality of Life (VascuQol-6) is a valid, practical, and responsive instrument for the assessment of health-related QOL in patients with PAD. The main advantage is the compact format that offers a possibility for routine use in busy clinical settings. Range of scores and what they represent: Each question is scored 1-4. The total score is achieved by summarizing the score on each question, resulting in a score between 6 and 24. Higher value indicates better health status. |
Change from Baseline to Up to 6 Months
|
|
Vascular Quality of Life Questionnaire-6 (VascuQol6)
Tidsramme: Change from Baseline to Week 18
|
The six-item Vascular Quality of Life (VascuQol-6) is a valid, practical, and responsive instrument for the assessment of health-related QOL in patients with PAD. The main advantage is the compact format that offers a possibility for routine use in busy clinical settings. Range of scores and what they represent: Each question is scored 1-4. The total score is achieved by summarizing the score on each question, resulting in a score between 6 and 24. Higher value indicates better health status. |
Change from Baseline to Week 18
|
|
Absolute Claudication Distance (ACD)
Tidsramme: Change from Baseline to Up to 6 Months
|
ACD is defined as the walking distance after which a patient had to stop walking to relieve claudication pain.
Distance is measured in meters
|
Change from Baseline to Up to 6 Months
|
|
Functional Claudication Distance (FCD)
Tidsramme: Change from Baseline to Up to 6 Months
|
FCD is defined as the distance a patient would prefer to stop because of claudication pain.
Distance is measured in meters.
|
Change from Baseline to Up to 6 Months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Kamal Gupta, MD, University of Kansas Medical Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00140692
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Perifer arteriell sykdom
-
Mayo ClinicPåmelding etter invitasjonAnatomi av GSV for Rescue Peripheral IV AccessForente stater
-
Nanfang Hospital, Southern Medical UniversityFullførtLeverskade | Hepatecellulært karsinom | HAIC (Kjemoterapi via leverarterieinfusjon) | TACE(Transcatheter Arterial Chemoembolization)Kina
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada og andre samarbeidspartnereRekrutteringTwin Reversal Arterial Perfusion SyndromeSpania, Tyskland, Israel, Belgia, Nederland, Canada, Forente stater, Østerrike, Frankrike, Italia, Storbritannia
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
Nanfang Hospital, Southern Medical UniversityRekrutteringBevacizumab | Hepatecellulært karsinom | QL1706 | RALOX-HAIC (Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin) | Type VP3/4 Portåre tumor trombose | Iparomlimab og Tuvonralimab-injeksjonKina
-
Zhongda HospitalRekrutteringCT | HCC - Hepatocellulært karsinom | TACE(Transcatheter Arterial Chemoembolization)Kina
-
University of MiamiAktiv, ikke rekrutterendeTvilling til tvillingtransfusjonssyndrom | Tvilling; Kompliserer graviditet | Twin Reversal Arterial Perfusion Syndrome | Monokorionisk diamniotisk placenta | Monokorial monoamniotisk placentaForente stater
-
Boston Children's HospitalRekrutteringGraviditetsrelatert | Mors; Fremgangsmåte | Fosterets tilstander | Tvilling Monochorionic Monoamniotic Placenta | Tvilling til tvillingtransfusjonssyndrom | Twin Reversal Arterial Perfusion Syndrome | Vasa Previa | In utero-prosedyre som påvirker foster eller nyfødt | Chorion; Unormal | KorioangiomForente stater
Kliniske studier på Cardiac Rehabilitation Program
-
Karaganda Medical UniversityFullførtCOVID-19 | Oksydativt stress | Kognitive svekkelserKasakhstan
-
Mayo ClinicJohns Hopkins University; University of California, Irvine; University of...FullførtKardiovaskulære sykdommer | Telemedisin | HjertehendelseForente stater
-
University of PennsylvaniaIndependence Blue Cross; CardaHealthFullførtHjertefeilForente stater
-
Karolinska InstitutetFullførtSlag | Afasi | Apraxia av taleSverige
-
Sevval YesilkırHar ikke rekruttert ennåHjerneslag, iskemisk | Overlevende av kronisk slagTyrkia (Türkiye)
-
Medipol UniversityFullførtSlag | Bevisbasert praksis | FysioterapeutTyrkia (Türkiye)
-
Slb PharmaUniversité de Caen Normandie; NeoXpériences, Carpiquet, FranceHar ikke rekruttert ennåHjernesykdommer | Multippel sklerose | Cerebral parese | Iskemisk hjerneslag | Hodeskade | Nevrologiske tilstander | Parkinsons sykdom (PD) | Cerebral anoksiFrankrike
-
Emory UniversityNational Institute on Aging (NIA)FullførtProdromal Alzheimers sykdomForente stater
-
Stanford UniversityUniversity of California, BerkeleyTilbaketrukket